Plain-English translation of NCT07221149 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called combined with standard chemotherapy against another immunotherapy drug combined with chemotherapy for people with advanced stomach or esophageal cancer that has not been treated before. The study wants to see which combination works better and is safer for patients. About 690 people will be enrolled to compare these two treatment approaches.
Advanced stomach and esophageal cancers are very difficult to treat, and doctors are looking for more effective options. This medication is being tested to see if it can help patients live longer and have fewer side effects than currently available treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either plus chemotherapy or plus chemotherapy. You will have regular clinic visits for blood tests, imaging scans, and physical exams to monitor how well the treatment is working and to check for side effects. The study involves both a Phase 2 portion (which helps establish the right dose and safety profile) and a Phase 3 portion (which compares the treatments in a larger group). Your doctor will explain the full schedule of visits and treatment duration with you.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States